Xcout IntelPrelude Therapeutics Incorporated competitors & alternatives
The 12 closest competitors and alternatives to Prelude Therapeutics Incorporated among biotechnology companies — ranked by similarity to what Prelude Therapeutics Incorporated actually does, not by market-cap band.
Subscribe to see Prelude Therapeutics Incorporated’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Prelude Therapeutics Incorporated
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Prelude Therapeutics Incorporated at a glance
Prelude Therapeutics Incorporated is a biotechnology company headquartered in Wilmington, United States, founded in 2016. It is publicly listed (PRLD) with a market capitalisation of $261.9M. Xcout tracks 24 named people at Prelude Therapeutics Incorporated, including Kris Vaddi (Chief Executive Officer).
Prelude Therapeutics Incorporated leadership
- Kris VaddiChief Executive Officer
- Bryant David LimChief Financial Officer, Chief Legal Officer & Corporate Secretary
- Bryant LimChief Financial Officer & Chief Legal Officer
- Peggy A. ScherleChief Scientific Officer
- Andrew CombsExecutive Vice President & Chief Chemistry Officer
- Charles MorrisChief Medical Officer
18 more named people on record for Prelude Therapeutics Incorporated, with roles, board committees and tenure — see the full roster →
Top 12 Prelude Therapeutics Incorporated competitors
Ranked by semantic similarity — how close each company is to Prelude Therapeutics Incorporated by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Biotech
Blueprint Medicines Corporation is a global precision therapy company that invents life-changing medicines, operating as a Sanofi company.
Biotech
Aptose Biosciences Inc. is a clinical-stage biotechnology company that develops small molecule cancer therapeutics, focusing on precision medicines for hematologic malignancies. The company's product pipeline features investigational drug candidates such as tuspetinib and luxeptinib, which are designed to treat conditions like acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and B-cell malignancies.
Biotech
Alterome Therapeutics, Inc. is a clinical-stage precision oncology company headquartered in San Diego, California, founded in 2021. The privately held biotech firm focuses on developing targeted therapies to address genomically defined cancer drivers and intractable oncological targets.
Biotech
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Similar biotechnology company
Turning Point Therapeutics is a clinical-stage precision oncology company based in San Diego, California, that designs and develops targeted cancer therapies. Founded in 2013, the company operates as a subsidiary of Bristol Myers Squibb following its acquisition in 2022.
Biotech
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Similar biotechnology company
Apeiron Therapeutics is a clinical-stage biopharmaceutical and precision oncology company focused on developing biomarker-driven therapeutics for cancer.
Similar biotechnology company
Core Biomedicine is a preclinical-stage biotechnology and pharmaceutical manufacturing company pioneering lineage-based precision oncology therapeutics.
Biotech
Orum Therapeutics is a biotechnology research company specializing in the development of targeted protein degraders for precision oncology using its TPD² approach. The company is headquartered in Daejeon, South Korea, with additional offices in Boston, Massachusetts.
Biotech
Fore Biotherapeutics is a virtual precision oncology company rooted in science and innovation, with expertise and talent across the USA. The company is focused on developing treatments, including its Plixorafenib Program.
Similar biotechnology company
DCx Biotherapeutics is a Canadian preclinical-stage biotechnology company developing precision oncology therapeutics and precision drug conjugates to target genetically defined cancers. The company focuses on addressing root drivers and key cellular interdependencies of cancer lesions.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Prelude Therapeutics Incorporated and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Prelude Therapeutics Incorporatedand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →